Bull & Bear

Bull and Bear

Verdict: Watchlist — the decisive variable does not print until early 2027, and management itself has already guided FY26 Evernorth adjusted OI below FY25. The bull case rests on a real, observable mispricing: 9.3x FY26 adjusted EPS, a 10.7% trailing FCF yield, and the lowest MCR in managed care at 84.4%. The bear case rests on a structural margin reset already mid-flight — Q1 FY26 Pharmacy Benefit Services adjusted OI fell ~28% YoY, and federal law (CAA 2026: 100% ERISA rebate pass-through Aug 2028, Part D list-price ban Jan 2028) is pulling out the take-rate that funded the buyback engine. The single most important tension is whether the rebate-free pivot is a clearing event or a margin cliff — decided by the FY27 Evernorth adjusted OI guide that lands with FY26 results in ~Feb 2027.

Bull Case

The strongest bull points center on a verifiable valuation gap, leadership share inside a PBM triopoly, and a Healthcare book whose mix profile is genuinely different from the peers that have been broken this cycle.

Bull target: $400 over 18 months via 12x FY27 adjusted EPS of ~$33.50 (FY26 guide $30.35 plus ~5% operating growth and buyback to ~250M shares). The 12x multiple is the midpoint between today's 9.3x and ELV's 14.3x — a partial PBM-overhang clearing rather than a peer-best re-rate. Cross-checks to a $86.7B SOTP high-end equity value (~$329-347/sh depending on share count). Disconfirming signal: Cigna Healthcare MCR prints above 84.7% in Q2 or Q3 FY26 OR Express Scripts Rx claim growth falls below 3% with retention slipping below 95%.

Bear Case

The strongest bear points are not stylistic — they are management's own guide, a single-counterparty concentration that is rising not stable, and a forensic overlay that lives under active securities litigation.

Bear downside target: $210 over 12-18 months via forward-12-month adjusted EPS held flat at ~$30 × 7x (vs current 9.3x), reflecting PBM regulatory-margin doubt now that the rebate model is being legislated away. SOTP cross-check (Evernorth 7x EBIT on $6.5B FY27, Healthcare 8-9x EBIT on $4.0B, less $24B net debt) lands in $155-190/sh — supportive of $210 as a generous bear case rather than the floor. Cover signal: Q4 FY26 print where (i) FY27 Evernorth adj OI is guided to $7.2B+ with PBM client retention disclosed at 95%+ AND (ii) Centene contract is publicly extended or expanded beyond 2030. Either alone keeps the short alive; both together kill it.

The Real Debate

Three tensions where Bull and Bear interpret the same underlying fact differently. Each has a concrete, observable resolution.

Verdict

Watchlist. The bear carries more weight on the substance because management's own FY26 Evernorth guide of "at least $6.9B" sits below the FY25 $7.2B print, Q1 FY26 PBS adjusted OI is already down ~28% YoY, and the federal-law catalyst (CAA 2026 rebate pass-through Aug 2028; Part D list-price ban Jan 2028) is dated and unconditional — the structural reset is not a fear, it is partially in the numbers. The single most decisive tension is whether the rebate-free pivot is a clearing event or a margin cliff, and that question is not answerable until the FY27 Evernorth adjusted OI guide prints with FY26 results in ~Feb 2027. The bull could still be right: 9.3x FY26 adjusted EPS with a 10.7% FCF yield, the lowest MCR in managed care at 84.4%, mega-client renewals through 2029-2030, and a Q1 FY26 print that already cleared the bar that broke Humana and CVS together represent a wider margin of safety than the bear discount allows for. The verdict flips to Lean Long if Q2 or Q3 FY26 MCR prints inside the 83.7-84.7% guide AND the FY26 investor day reclaims a $7.0B+ Evernorth FY27 floor; it flips to Avoid if FY27 Evernorth is guided below $6.9B OR an adverse motion-to-dismiss in the Bernstein Litowitz / Ascent case forces expanded related-party rebate disclosure into the FY26 10-K. Until one of those prints, the multiple is too cheap to short and the structural overhang is too live to own.